|
Market Cap (24-Jun) $24,941,990 (1,259th) |
Close (30-Jun) $0.080 |
Volume (30-Jun) 244,049 |
Shortsold (15-Jan) 38,875 (0.01%) (540th) |
|
52w High $0.260 |
52w Low $0.059 |
P/E - |
EPS -0.02 |
NSB released this announcement to the ASX on 11 March 2022, 8:19. The announcement is marked as price sensitive, and is 3 page(s) in length and 258.11kb in size.
You can view all announcements from NSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, NSB was 0.012% short sold according to ASIC data. It was ranked the 639th most shorted stock on the ASX. It is now ranked as the 540th most shorted stock on the ASX with 0.012% of total shares short sold as of the latest reported data (15 January 2026).
| Other Recent Announcements from NSB | |
|---|---|
| Change of Director's Interest Notice - Rennie | 7 June 2023, 8:22 |
| Change of Director's Interest Notice - Uvarov | 25 May 2023, 15:30 |
| Change of Director's Interest Notice - Rennie | 25 May 2023, 15:07 |
| New data demonstrates EmtinB activity in autoimmune diseases | 11 March 2022, 8:19 |
| NSB 1HY22 Key Activity Highlights | 28 February 2022, 10:03 |
| Half Yearly Report and Accounts | 28 February 2022, 9:45 |
| Successful completion of key studies in lead up to Phase I | 8 February 2022, 8:23 |
You must be logged in to post a reply.
NeuroScientific Biopharmaceuticals 